Navigation Links
BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytren's Contracture in Europe
Date:4/11/2011

$7.5 million milestone payment ($30 million in aggregate) made as a result of the first commercial sale in each additional major European market; France, Italy, Germany and Spain. In addition BioSpecifics will receive 8.5% of all additional sublicense income Auxilium receives from Pfizer. BioSpecifics will also continue to receive low double-digit royalties on sales, independent of indication, territory, sales volume and whether Auxilium or Pfizer sells the product. In addition, BioSpecifics will receive a markup on the cost of goods sold.

Further details and product information will be available in the European Public Assessment Report on the web site of the European Medicines Agency at www.emea.europa.eu.

About Dupuytren's Contracture

Dupuytren's contracture is caused by an abnormal accumulation of collagen in the palm of the hand characterized by the formation of nodules or lumps in the early stages. As the disease progresses, a cord is formed and the fingers may become progressively contracted.

About XIAPEX (Collagenase clostridium histolyticum)

Collagenase clostridium histolyticum is a combination of two purified collagenases (collagenase is an enzyme capable of breaking down collagen), derived from the bacterium Clostridium histolyticum. It is the first pharmacological treatment to be developed for Dupuytren's contracture and may be an alternative to invasive and often complicated surgery for patients in the EU. Collagenase clostridium histolyticum is administered by local injection directly into the Dupuytren's cord - a procedure which can be carried out in an outpatient setting. It works by breaking down the structure of the cord and, 24 hours after injection, a finger extension procedure can be carried out as necessary to break the cord and allow extension of the finger. If contracture remains four weeks after treatment, another injection can be administered into th
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
2. BioSpecifics Technologies Corp. Amends Its Rights Agreement
3. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
5. BioSpecifics Technologies Corp. to Present at BioCentury Newsmakers in the Biotech Industry Conference
6. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2010 Financial Results on August 6, 2010
8. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
9. BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
11. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/29/2015)... 2015 Educating the community continues to ... the Advancement of Wound Care (AAWC), which was ... AAWC,s corporate partners, the Association provides medical professionals ... AAWC website at http://aawconline.org/education-for-the-generalist/ . The portal ... links to various CME/CEU educational programs. This education ...
(Date:5/28/2015)... and HOUSTON , May 28, ... (TSX-V: EPI) today reported financial results for the second quarter ... unless specified otherwise, are expressed in Canadian dollars and in ... Summary Results ESSA recorded a net loss ... months ended March 31, 2015 (Q2-2015), compared to a net ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... 2012 Allscripts (NASDAQ: MDRX) today announced that ... ™ to manage the revenue cycle for 39 affiliated providers ... integrated Allscripts Electronic Health Record (EHR) to automate ... the insights they need to deliver superior patient care. ...
... SAN FRANCISCO, Jan. 4, 2012  Practice Fusion, the ... community in the US, announced today that its ... a faster, simpler and more streamlined user experience ... technology flagged more than 7,000 deadly drug interactions ...
Cached Medicine Technology:Mammoth Hospital Selects Allscripts RCM Services 2Mammoth Hospital Selects Allscripts RCM Services 3Mammoth Hospital Selects Allscripts RCM Services 4Mammoth Hospital Selects Allscripts RCM Services 5Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:5/30/2015)... Il (PRWEB) May 30, 2015 Promising ... Clinical Oncology (ASCO) Annual Meeting 2015 show activity of ... in one case specifically against brain metastases and in ... breast cancer patients. , "I am thrilled to have ... in her early 40s. She didn't have any other ...
(Date:5/30/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 30, 2015 ... safe, and simple procedure to lighten or stop ... risks of hysterectomy. This procedure can reduce or stop ... the lining of the uterus (the part that causes ... , About 10 million women suffer from heavy menstrual ...
(Date:5/30/2015)... One of the pervasive problems plaguing the ... available. Often, the ruralness of a location can severely ... areas feeling the crunch of a strained healthcare system, ... paying high premiums and copays, Online USA Doctors ... via the power of the internet. , ...
(Date:5/30/2015)... 30, 2015 Boston Scientific Corp. ... punitive and compensatory damages to a transvaginal mesh ... complications following implantation of the company’s Pinnacle and ... on May 28th in Delaware Superior Court, the ... after the jury found that the implants were ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 EHO offers ... Web Portal that gives hospices the ability to manage ... Because of this business model, EHO has been able ... pricing to its clients and survive among the giants ... hospice management systems three years ago, it has simplified ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4
... Diabetes mellitus is an independent risk factor for cardiovascular ... risk by 2-6 fold relative to nondiabetic subjects and ... mellitus patients will die of an atherosclerotic event. In ... cardiovascular disease, and so the presence of even borderline-high-risk ...
... and his colleagues from Southampton University have found a new ... of two or more genes fuse. The research team is ... common form of childhood leukemia, which is called as Acute ... to develop this genetic test. The treatment is given by ...
... Alzheimer’s disease (AD) is one of the most common forms ... the parts of the brain that control thought, memory, and ... an association between AD risk and several vitamins and have ... that total intake of folate at or above the RDA ...
... been demonstrated that our own experience is important to exhibit ... have been working hard to understand what happens in our ... action. The results of the observation show that the actions ... , ,The research points out that we understand the ...
... and vegetables can pave way for a long and healthy ... out that fruits and vegetables can cause dangerous interactions when ... the activity and toxicity of orally administered drugs. The effect ... ,One of the most studied or well documented of these ...
... approximately one in every 1,000 children and is characterized ... factors have been as causative factors for the disorder. ... the age of 16. There is no satisfactory treatment ... symptoms significantly. , ,The five most common types ...
Cached Medicine News:Health News:Feelings Of Sympathy And Empathy Dictated by Personal Experience 2Health News:Feelings Of Sympathy And Empathy Dictated by Personal Experience 3Health News:Guidelines for treatment of juvenile idiopathic arthritis formulated 2
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
Medicine Products: